Management of stable CAD FFR guided therapy: the new gold standard
|
|
- Stephanie Cook
- 5 years ago
- Views:
Transcription
1 Management of stable CAD FFR guided therapy: the new gold standard Suleiman Kharabsheh, MD Director; CCU, Telemetry and CHU Associate professor of Cardiology, Alfaisal Univ. KFHI - KFSHRC
2 Should patients with stable ischemic heart disease undergo revascularization?
3 SIHD The answer is less clear for these patients than for patients with ACS Benefits may be limited to the improvement of angina (has been recently challenged, ORBITA)! Uncertainty about the benefit of routine revascularization in this cohort (COURAGE)
4 Risk stratification Only patients with documented myocardial ischaemia involving 10% of the LV myocardium have a lower CV and all-cause mortality when revascularization is performed Revascularization may increase mortality in patients with ischaemia involving,10% of the myocardium Eur Heart J 2011;32: Circulation 2003;107:
5 Circulation 2003;107: Relationship between cardiac mortality and extent of myocardial ischemia *P < 0.02
6 Annual Mortality with Medical Therapy Circulation 1994; 89:
7 MEDICAL THERAPY FOR ALL Lipid management Blood pressure management Physical activity Weight management Smoking cessation Antiplatelet therapy Beta-blockers for patients with normal LVF after ACS, and for those with an ejection fraction of < 40% ACE-I or ARB for patients who have hypertension, diabetes, LVEF < 40% or CKD Annual influenza vaccination Anti-ischemic medications (betablockers, calcium channel blockers, nitrates) for relief of symptoms
8
9 Aim of the COURAGE Trial To determine whether PCI plus OMT reduces the risk of death or nonfatal MI in symptomatic patients with stable CAD, as compared with OMT alone. 2,287 patients included in COURAGE, were a low-risk subset of the more than 35,000 patients initially evaluated 2.5 to 7 year (mean 4.6 year) follow-up
10 Baseline Nuclear Imaging* Reversible Perfusion Defects Single 23% Multiple 67% LVEF% 61% (mean) *60% of subjects had baseline nuclear stress testing
11 Baseline Angiographic Disease Severity 31% 30% 3 VD 1 VD 2 VD 1 VD 2 VD 3 VD 39%
12 Survival Free of Death from Any Cause and Myocardial Infarction 1.0 Optimal Medical Therapy (OMT) PCI + OMT Hazard ratio: % CI ( ) P = 0.62 Number at Risk Years Medical Therapy PCI
13 Survival Free of Hospitalization for ACS OMT PCI + OMT Hazard ratio: % CI ( ) P = Number at Risk Years Medical Therapy PCI
14 Freedom from Angina During Long-Term Follow-up Characteristic PCI + OMT OMT CLINICAL Angina free no. Baseline 12% 13% 1 Yr 66% 58% 3 Yr 72% 67% 5 Yr 74% 72% The comparison between the PCI group and the medical-therapy group was significant at 1 year ( P<0.001) and 3 years (P=0.02) but not at baseline or 5 years.
15 ORBITA trial 230 enrolled Dec Jul 2017 in 5 UK sites Medical optimization phase 30 patients exited 200 patients randomized PCI (n=105) Placebo (n=95) Blinded follow-up phase 4 patients did not complete follow-up Follow-up (n=105) Follow-up (n=91)
16 Stenosis severity PCI n = 105 Placebo n = 95 P Area stenosis by QCA (%) (SD 10.2) (SD 10.3) FFR (SD 0.16) (SD 0.16) ifr (SD 0.22) (SD 0.21)
17 Change in exercise time (seconds) Primary endpoint result Change in total exercise time (SD 86.3) p= sec (-8.9 to 42.0) p= PCI 11.8 (SD 93.3) p=0.235 Placebo Error bars are standard errors of the mean
18 Secondary endpoint results Blinded evaluation of ischaemia reduction Peak stress wall motion index score Pre-randomization Follow-up Δ (Pre-randomization to follow-up) Difference in Δ between arms PCI n = (0.18) 1.03 (0.06) (0.17) p< Placebo n = (0.18) 1.13 (0.19) 0.02 (0.16) p= (-0.15 to -0.04) p=0.0011
19
20 Conclusions ORBITA is the first placebo-controlled randomized trial of PCI in stable angina PCI significantly reduced ischemic burden as assessed by stress echo In this single vessel, angiographically guided trial there was no difference in exercise time increment between PCI and placebo
21 Why Do We Need FFR? The noninvasive test is a useful gatekeeper to decide which patients warrant invasive coronary angiography MPI lacks spatial resolution, particularly in MVD In the majority of patients undergoing CAG /PCI, noninvasive stress imaging has not been performed (50%). JAMA. 2008;300:
22 Concept of FFR Maximum flow down a vessel in the presence of a stenosis compared to the maximum flow in the hypothetical absence of the stenosis Pijls and De Bruyne, Coronary Pressure Kluwer Academic Publishers, 2000
23
24 Advantages of FFR FFR is extremely reproducible Independent of hemodynamic changes Narrow cutoff range ( ) Superb spatial resolution Specific for epicardial stenosis Independent of the microvasculature Accounts for collateral flow
25 Is Coronary Angio alone a good tool to judge CAD severity? Fractional Flow Reserve Versus Angiography for Multi-vessel Evaluation (FAME) trial
26 FAME Trial
27 FAME primary end point
28 FAME
29 Approximately one fourth of the deferred lesions appeared >70% narrowed on visual interpretation of the angiogram!
30 Is deferral of PCI safe in SCAD if FFR > 0.75?
31 DEFER study 325 patients 181 patients FFR > 0.75 => No ischaemia Randomisation 144 patients FFR < 0.75 => Ischaemia PTCA 144 patients Performance of PTCA 90 patients 2 yr follow-up Deferral of PTCA 91 patients 2 yr follow-up Bech et al, Circulation 2001
32
33 DEFER Study Result at 5 years
34
35
36
37 Stable CAD patients scheduled for 1, 2 or 3 vessel DES-PCI N = 1220 Randomized Trial FFR in all target lesions Registry At least 1 stenosis with FFR 0.80 (n=888) When all FFR > 0.80 (n=332) Randomization 1:1 PCI + MT 73% MT 27% MT 50% randomly assigned to FU Follow-up after 1, 6 months, 1, 2, 3 and 5 years
38 Importance of Ischemia COURAGE FAME 2 No/limited Ischemia 69% 100% of randomized patients had (extensive) myocardial Ischemia Courtesy of: Bernard De Bruyne Mean FFR value of 0.68 in large epicardial arteries
39 Primary Endpoint: Death, MI, Urgent Revasc Cumulative incidence (%) 30 No. at risk MT PCI+MT Registry 0 PCI+MT vs. MT: HR 0.32 ( ); p<0.001 PCI+MT vs. Registry: HR 1.29 ( ); p=0.61 MT vs. Registry: HR 4.32 ( ); p< Months after randomization De Bruyne, et al. New Engl J Med 2012;367:
40 FAME 2 2 years 8.1% in the PCI group vs 19.5% in the MT group (HR 0.39, P <0.001)
41 FAME 2 2 years After 2 years, 179 patients (40.6%) in the medical - therapy group had crossed over to undergo PCI, whereas 36 patients (8.1%) in the PCI group had undergone repeat revascularization (HR 0.16, P < 0.001)
42 3 Year Clinical Outcome and Cost-Effectiveness of FFR- Guided PCI in Stable Patients with Coronary Artery Disease: FAME 2 Trial William F. Fearon, MD, Takeshi Nishi, MD, Bernard De Bruyne, MD, PhD, Derek B. Boothroyd, PhD; Emanuele Barbato, MD, PhD, Pim Tonino, MD, PhD, Peter Ju ni, MD, Nico H.J. Pijls, MD, PhD, and Mark A. Hlatky, MD for the FAME 2 Trial Investigators
43 Objective Evaluate the long-term clinical outcomes, effects on quality of life, and cost-effectiveness of FFR-guided PCI versus medical therapy alone in patients with stable coronary artery disease enrolled in the FAME 2 trial.
44 Results: Clinical Outcome Three Year Rate of Death, MI, or Urgent Revascularization *P value compares PCI + MT patients with MT patients
45 Results: Quality of Life % of Patients with Class II-IV Angina at each Time Point % with CCS II-IV Angina
46 Results: Costs
47 Importance of Myocardial Ischemia With greater degrees of ischemia, there is a survival benefit for PCI P<0.001 Hachamovitch, et al. Circulation 2003;107:
48 Conclusion Ischemic Burden is the key determinant in Stable CAD patients Ischemia-guided coronary revascularization (FFR) improves long term outcomes while reducing cost compared with angiography guided approach
49 Inaccuracy of Radionuclide Imaging JACC 2010;3:315-7.
50 What's in the Pipeline ISCHEMIA STUDY
51
FFR Incorporating & Expanding it s use in Clinical Practice
FFR Incorporating & Expanding it s use in Clinical Practice Suleiman Kharabsheh, MD Consultant Invasive Cardiology Assistant professor, Alfaisal Univ. KFHI - KFSHRC Concept of FFR Maximum flow down a vessel
More information3 Year Clinical Outcome and Cost-Effectiveness of FFR- Guided PCI in Stable Patients with Coronary Artery Disease: FAME 2 Trial
3 Year Clinical Outcome and Cost-Effectiveness of FFR- Guided PCI in Stable Patients with Coronary Artery Disease: FAME 2 Trial William F. Fearon, MD, Takeshi Nishi, MD, Bernard De Bruyne, MD, PhD, Derek
More informationBenefit of Performing PCI Based on FFR
Benefit of Performing PCI Based on FFR William F. Fearon, MD Associate Professor Director, Interventional Cardiology Stanford University Medical Center Benefit of FFR-Guided PCI FFR-Guided PCI vs. Angiography-Guided
More informationFractional Flow Reserve: Review of the latest data
Fractional Flow Reserve: Review of the latest data Michalis Hamilos, MD, PhD, FESC University Hospital of Heraklion Fractional Flow Reserve (FFR) Coronary angiography does not always tell the truth Most
More informationPCIs on Intermediate Lesions NCDR Cath-PCI Registry
Practical Application Of Coronary Physiology in The Cath Lab Talal T Attar, MD, MBA, FACC PCIs on Intermediate Lesions NCDR Cath-PCI Registry Fraction of stenoses 50-70% treated with PCI without further
More informationPCI for Stable Ischemic Heart Disease: What Happened in the Last Week?
PCI for Stable Ischemic Heart Disease: What Happened in the Last Week? Ajay J. Kirtane, MD, SM Center for Interventional Vascular Therapy Columbia University Medical Center / NewYork Presbyterian Hospital
More informationFFR in Multivessel Disease
FFR in Multivessel Disease April, 26 2013 Coronary Physiology in the Catheterization Laboratory Location: European Heart House, Nice, France Pim A.L. Tonino, MD, PhD Hartcentrum, Eindhoven, the Netherlands
More informationCost-Effectiveness of Fractional Flow Reserve
Cost-Effectiveness of Fractional Flow Reserve William F. Fearon, MD Associate Professor of Medicine Director, Interventional Cardiology Stanford University Medical Center Cost-Effectiveness of FFR What
More informationFractional Flow Reserve: Basics, FAME 1, FAME 2. William F. Fearon, MD Associate Professor Stanford University Medical Center
Fractional Flow Reserve: Basics, FAME 1, FAME 2 William F. Fearon, MD Associate Professor Stanford University Medical Center Conflict of Interest Advisory Board for HeartFlow Research grant from St. Jude
More informationFFR-Guided PCI. 4 th Imaging and Physiology Summit October 29 th, 2010 Seoul, Korea. Stanford
4 th Imaging and Physiology Summit October 29 th, 2010 Seoul, Korea FFR-Guided PCI William F. Fearon, M.D. Associate Professor Division of Cardiovascular Medicine University Medical Center Disclosure Statement
More informationPCI reduces death/myocardial infarction in stable patients with silent ischemia
PCI reduces death/myocardial infarction in stable patients with silent ischemia Stephane Fournier, Yuhei Kobayashi, William F. Fearon, Bruno Roza da Costa, Carlos Collet, Panos Xaplanteris, Frederik Zimmerman,
More informationΣεμινάριο Ομάδων Εργασίας Fractional Flow Reserve (FFR) Σε ποιούς ασθενείς; ΔΗΜΗΤΡΗΣ ΑΥΖΩΤΗΣ Επιστ. υπεύθυνος Αιμοδυναμικού Τμήματος, Βιοκλινική
ΕΛΛΗΝΙΚΗΚΑΡΔΙΟΛΟΓΙΚΗΕΤΑΙΡΕΙΑ Σεμινάριο Ομάδων Εργασίας 2011 Fractional Flow Reserve (FFR) Σε ποιούς ασθενείς; ΔΗΜΗΤΡΗΣ ΑΥΖΩΤΗΣ Επιστ. υπεύθυνος Αιμοδυναμικού Τμήματος, Βιοκλινική GUIDELINES ON MYOCARDIAL
More informationRelations of Interest
Relations of Interest Consulting Fees on my behalf go to the Cardiovascular Research Center Aalst Contracted Research between the Cardiovascular Research Center Aalst and several pharmaceutical and device
More informationFractional Flow Reserve and the Results of the FAME Study
Imaging and Physiology Summit Seoul, Korea November 21 st, 2009 Fractional Flow Reserve and the Results of the FAME Study William F. Fearon, M.D. Assistant Professor Division of Cardiovascular Medicine
More informationThe Case for PCI as the Preferred Therapy in Most Patients with Chronic Stable Angina
The Case for PCI as the Preferred Therapy in Most Patients with Chronic Stable Angina Ajay J. Kirtane,, MD Columbia University Medical Center The Cardiovascular Research Foundation Conflict of Interest
More informationDisclosures. Speaker s bureau: Research grant: Advisory Board: Servier International, Bayer, Merck Serono, Novartis, Boehringer Ingelheim, Lupin
Disclosures Speaker s bureau: Research grant: Advisory Board: Servier International, Bayer, Merck Serono, Novartis, Boehringer Ingelheim, Lupin Servier International, Boehringer Ingelheim Servier International,
More informationAngor Stable: de COURAGE à FAME 2. Maladie coronaire stable et coronarographie en De COURAGE à FAME 2
Maladie coronaire stable et coronarographie en 2013 De COURAGE à FAME 2 Bernard De Bruyne, MD, PhD Cardiovascular Center Aalst OLV-Clinic Aalst, Belgium COURAGE Trial Aim To compare optimal medical therapy
More informationCLINICAL CONSEQUENCES OF THE
CLINICAL CONSEQUENCES OF THE FAME STUDY TCT ASIA Seoul, Korea, april 26 th, 2012 Nico H. J. Pijls, MD, PhD Catharina Hospital, Eindhoven, The Netherlands GUIDELINES ESC SEPTEMBER 2010 FFR UPGRADED TO LEVEL
More informationCoronary artery disease (CAD): Fractional Flow Reserve (FFR) for Pilots Risk Assessment. B. Haaff, R. Quast
Coronary artery disease (CAD): Fractional Flow Reserve (FFR) for Pilots Risk Assessment B. Haaff, R. Quast Aeromedical Center Germany, Stuttgart-Airport Westpfalz-Klinikum, Kaiserslautern, Germany Disclosure
More informationDebate Should we use FFR? I will say NO.
Debate Should we use FFR? I will say NO. Hyeon-Cheol Gwon Cardiac and Vascular Center Samsung Medical Center Sungkyunkwan University School of Medicine Dr. Hyeon-Cheol Gwon Research fund from Abbott Korea
More informationImaging ischemic heart disease: role of SPECT and PET. Focus on Patients with Known CAD
Imaging ischemic heart disease: role of SPECT and PET. Focus on Patients with Known CAD Hein J. Verberne Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands International Conference
More informationControversies in Coronary Revascularization. Atlanta CCU April 15, 2016
Controversies in Coronary Revascularization Atlanta CCU April 15, 2016 Habib Samady MD FACC FSCAI Professor of Medicine Director, Interventional Cardiology, Emory University Director, Cardiac Catheterization
More informationFFR-CT Not Ready for Primetime
FFR-CT Not Ready for Primetime Leslee J. Shaw, PhD, MASNC, FACC, FAHA, FSCCT R. Bruce Logue Professor of Medicine Co-Director, Emory Clinical CV Research Institute Emory University School of Medicine Atlanta,
More informationFractional Flow Reserve Guided PCI versus Medical Therapy in Stable Coronary Disease. FAME 2 Trial
Fractional Flow Reserve Guided PCI versus Medical Therapy in Stable Coronary Disease FAME 2 Trial Clinicaltrials.gov NCT01132495 Bernard De Bruyne, Nico H.J. Pijls, William F Fearon, Peter Juni, Emanuele
More informationDave Kettles, St Dominics Hospital East London.
Dave Kettles, St Dominics Hospital East London. 110 x 150 Angina for a couple of months Trop T negative T wave inversion across the chest leads Not wanting to risk radial Huge struggle with femoral
More informationManagement of Stable Ischemic Heart Disease. Vinay Madan MD February 10, 2018
Management of Stable Ischemic Heart Disease Vinay Madan MD February 10, 2018 1 Disclosure No financial disclosure. 2 Overview of SIHD Diagnosis Outline of talk Functional vs. Anatomic assessment Management
More informationFRACTIONAL FLOW RESERVE: STANDARD OF CARE
FRACTIONAL FLOW RESERVE: FROM INVESTIGATIONAL TOOL TO STANDARD OF CARE TCT ASIA Seoul, Korea, april 26 th, 2012 Nico H. J. Pijls, MD, PhD Catharina Hospital, Eindhoven, The Netherlands FRACTIONAL FLOW
More informationStable Angina: Indication for revascularization and best medical therapy
Stable Angina: Indication for revascularization and best medical therapy Cardiology Basics and Updated Guideline 2018 Chang-Hwan Yoon, MD/PhD Cardiovascular Center, Department of Internal Medicine Bundang
More informationCoronary stenting: the appropriate use of FFR
Coronary stenting: the appropriate use of FFR Morton J. Kern, MD Professor of Medicine Chief of Cardiology LBVA Associate Chief Cardiology University California Irvine Orange, California To treat or not
More informationPCI vs. CABG From BARI to Syntax, Is The Game Over?
PCI vs. CABG From BARI to Syntax, Is The Game Over? Seung-Jung Park, MD, PhD Professor of Medicine, University of Ulsan College of Medicine Asan Medical Center, Seoul, Korea PCI vs CABG Multi-Vessel Disease
More informationFractional Flow Reserve and the 1 Year Results of the FAME Study
Imaging and Physiology Summit Seoul, Korea, November 22, 2008 Fractional Flow Reserve and the 1 Year Results of the FAME Study William F. Fearon, M.D. Assistant Professor Division of Cardiovascular Medicine
More informationCoronary interventions
Controversial issues in the management of ischemic heart failure Coronary interventions Maciej Lesiak Department of Cardiology, University Hospital in Poznan none DECLARATION OF CONFLICT OF INTEREST CHF
More informationTrial. International Study of Comparative Health Effectiveness with Medical and Invasive Approaches
Trial International Study of Comparative Health Effectiveness with Medical and Invasive Approaches Stable Ischemic Heart Disease What is the best initial management strategy for patients with SIHD? What
More information2/17/2010. Grace Lin, MD Assistant Professor of Medicine University of California, San Francisco
Modern Management of Patients with Stable Coronary Artery Disease Grace Lin, MD Assistant Professor of Medicine University of California, San Francisco Scope of the Problem Prevalence of CAD: 17.6 million
More informationFRACTIONAL FLOW RESERVE Step-by-step measurement, Practical tips & Pitfalls
FRACTIONAL FLOW RESERVE Step-by-step measurement, Practical tips & Pitfalls Ahmed M ElGuindy, MSc, MRCP(UK) Division of Cardiology Aswan Heart Centre 2013 Fractional Flow Reserve Essential diagnostic tool
More informationTreatment Options for Angina
Treatment Options for Angina Interventional Cardiology Perspective Michael A. Robertson, M.D. 10/30/10 Prevalence of CAD in USA 15 million Americans with CAD 2 million diagnostic catheterizations 1 million
More informationDo stents deserve the bad press? Mark A. Tulli MD, FACC
Do stents deserve the bad press? Mark A. Tulli MD, FACC Disclosures: None Introduction Stents don t help people. Stents are bad for patients. Heart Treatment Overused WSJ Study Finds Doctors Often Too
More informationCan Angiographic Complete Revascularization Improve Outcomes for Patients with Decreased LV Function? NO!
Can Angiographic Complete Revascularization Improve Outcomes for Patients with Decreased LV Function? NO! Young-Hak Kim, MD, PhD Heart Institute, University of Ulsan College of Medicine Asan Medical Center,
More informationCindy L. Grines MD FACC FSCAI
Cindy L. Grines MD FACC FSCAI Hofstra Northwell School of Medicine Chair, Cardiology Academic Chief of Cardiology, Northwell Health North Shore University Hospital, Manhasset NY Multivessel Disease in
More informationJames M. Kirshenbaum, MD, FACC
James M. Kirshenbaum, MD, FACC Associate Professor of Medicine Harvard Medical School Co-Director, Clinical Cardiology Director, Acute Interventional Cardiology Brigham and Women s Hospital Boston, MA
More informationFFR and CABG Emanuele Barbato, MD, PhD, FESC Cardiovascular Center Aalst, Belgium
FFR and CABG Emanuele Barbato, MD, PhD, FESC Cardiovascular Center Aalst, Belgium Conflict of Interest Institutional research grants and speaker s fee from St. Jude Medical and Boston Scientic to Cardiovascular
More informationFRACTIONAL FLOW RESERVE USE IN THE CATH LAB BECAUSE ANGIOGRAPHY ALONE IS NOT ENOUGH!!!!!!!!
FRACTIONAL FLOW RESERVE USE IN THE CATH LAB BECAUSE ANGIOGRAPHY ALONE IS NOT ENOUGH!!!!!!!! Juan Antonio Pastor-Cervantes,M.D FSCAI, FACC Cardiovascular Institute Memorial Regional Hospital Hollywood Florida
More informationSTEMI AND MULTIVESSEL CORONARY DISEASE
STEMI AND MULTIVESSEL CORONARY DISEASE ΤΣΙΑΦΟΥΤΗΣ Ν. ΙΩΑΝΝΗΣ ΕΠΕΜΒΑΤΙΚΟΣ ΚΑΡΔΙΟΛΟΓΟΣ Α ΚΑΡΔΙΟΛΟΓΙΚΗ ΝΟΣ ΕΡΥΘΡΟΥ ΣΤΑΥΡΟΥ IRA 30-50% of STEMI patients have additional stenoses other than the infarct related
More informationIntroducing. Integrated FFR Platform
Introducing Integrated FFR Platform Fractional Flow Reserve (FFR) Definition of FFR Maximum achievable blood flow in stenotic coronary artery divided by maximum blood flow in the same artery without stenosis.
More informationFractional Flow Reserve. A physiological approach to guide complex interventions
Fractional Flow Reserve A physiological approach to guide complex interventions What is FFR? Fractional Flow Reserve (FFR) is a lesion specific, physiological index determining the hemodynamic severity
More informationRevascularization in Severe LV Dysfunction: The Role of Inducible Ischemia and Viability Testing
Revascularization in Severe LV Dysfunction: The Role of Inducible Ischemia and Viability Testing Evidence and Uncertainties Robert O. Bonow, MD, MS, MACC Northwestern University Feinberg School of Medicine
More informationHow to approach non-infarct related artery disease in patients with STEMI in a limited resource setting
How to approach non-infarct related artery disease in patients with STEMI in a limited resource setting Ahmed A A Suliman, MBBS, FACP, FESC Associate Professor, University of Khartoum Interventional Cardiologist,
More informationFocus on Acute Coronary Syndromes
Focus on Acute Coronary Syndromes Emanuele Barbato, MD, PhD, FESC Cardiovascular Center Aalst, Belgium Potential conflicts of interest Consulting fees and honoraria on my behalf go to the Cardiovascular
More informationTRATAMIENTO INVASIVO ENFERMEDAD ISQUEMICA ESTABLE. Jonathan Poveda CLINICA BIBLICA 2015
TRATAMIENTO INVASIVO ENFERMEDAD ISQUEMICA ESTABLE Jonathan Poveda CLINICA BIBLICA 2015 COURAGE First coronary angioplasty lesion (circles) two days before (A), immediately after (B), and one month after
More informationApproach to Multi Vessel disease with STEMI
Approach to Multi Vessel disease with STEMI MANAGEMENT OF ST-ELEVATION MYOCARDIAL INFARCTION Dr. Thomas Alexander, M.D; D.M; F.A.C.C. Senior Consultant and Interventional Cardiologist Kovai Medical Centre
More informationNew Insight about FFR and IVUS MLA
New Insight about FFR and IVUS MLA Can IVUS MLA Predict FFR
More informationEvidence-Based Management of CAD: Last Decade Trials and Updated Guidelines
Evidence-Based Management of CAD: Last Decade Trials and Updated Guidelines Enrico Ferrari, MD Cardiac Surgery Unit Cardiocentro Ticino Foundation Lugano, Switzerland Conflict of Interests No conflict
More informationCoronary Artery Disease: Revascularization (Teacher s Guide)
Stephanie Chan, M.D. Updated 3/15/13 2008-2013, SCVMC (40 minutes) I. Objectives Coronary Artery Disease: Revascularization (Teacher s Guide) To review the evidence on whether percutaneous coronary intervention
More informationIntervention: How and to which extent is technology helping us?
Cardiological Society of India Congress 12th February 2016 Chennai, India Intervention: How and to which extent is technology helping us? SIMONE BISCAGLIA MD CARDIOVASCULAR INSTITUTE, FERRARA, ITALY Introduction
More informationStable Ischemic Heart Disease. Ivan Anderson, MD RIHVH Cardiology
Stable Ischemic Heart Disease Ivan Anderson, MD RIHVH Cardiology Outline Review of the vascular biology of atherosclerosis Why not just cath everyone with angina? Medical management of ischemic cardiomyopathy
More informationFFR? FFR-CT? Ischaemia testing?
FFR? FFR-CT? Ischaemia testing? Marco Zimarino, MD, PhD Institute of Cardiology - University G. d Annunzio, Chieti (Italy) Diagnostic management of patients with suspected stable CAD Risk stratification
More informationCT FFR: Are you ready to totally change the way you diagnose Coronary Artery Disease?
CT FFR: Are you ready to totally change the way you diagnose Coronary Artery Disease? Madan Mohan MD MRCP FACC CQO, Division of Cardiovascular Medicine University Hospitals Case Medical Center Assistant
More informationEvaluating Clinical Risk and Guiding management with SPECT Imaging
Evaluating Clinical Risk and Guiding management with SPECT Imaging Raffaele Giubbini Chair and Nuclear Medicine Unit University & Spedali Civili Brescia- Italy U.S. Congressional Budget Office. Technological
More informationROLE OF CORONARY PRESSURE & FFR IN MULTIVESSEL DISEASE
ROLE OF CORONARY PRESSURE & FFR IN MULTIVESSEL DISEASE Angioplasty Summit TCT ASIA Seoul, Korea, april 24th, 2008 Nico H. J. Pijls, MD, PhD Catharina Hospital, Eindhoven, The Netherlands A rather common
More informationFAME STUDY: 2-year Follow-Up & CLINICAL SUBGROUP ANALYSIS
Coronary Physiology In The Cathlab FAME STUDY: 2-year Follow-Up & CLINICAL SUBGROUP ANALYSIS Educational Training Program ESC European Heart House april 7th 9th 2011 Nico H.J.Pijls, MD, PhD Catharina Hospital,
More informationOptimal testing for coronary artery disease in symptomatic and asymptomatic patients
Optimal testing for coronary artery disease in symptomatic and asymptomatic patients Alexandre C Ferreira, MD Clinical Chief of Cardiology Jackson Health System Director, Interventional Cardiology Training
More informationPhysiology (FFR & IFR) is Essential in Daily Pratice. Martine Gilard Brest University - France
Physiology (FFR & IFR) is Essential in Daily Pratice Martine Gilard Brest University - France Background Invasive assessment of atherosclerotic coronary artery lesion Morphological assessment IVUS X-ray
More informationFractional Flow Reserve (FFR) Shown to Improve Patient Outcomes and Reduce Costs. Executive Summary
(FFR) Shown to Improve Patient Outcomes and Reduce s Keywords Fractional Flow Reserve, coronary artery disease, stenosis, blood flow blockages Published: 5 October 213 Citation: RadcliffeCardiology.com,
More informationCoronary Physiology the current state of play
Coronary Physiology the current state of play Background The concept of using the trans-stenotic pressure gradient in a diseased coronary artery as a measure to guide percutaneous coronary intervention
More informationRational use of imaging for viability evaluation
EUROECHO and other imaging modalities 2011 Rational use of imaging for viability evaluation Luc A. Pierard, MD, PhD, FESC, FACC Professor of Medicine Head, Department of Cardiology, CHU Liège, Belgium
More informationFractional Flow Reserve from Coronary CT Angiography (and some neat CT images)
Fractional Flow Reserve from Coronary CT Angiography (and some neat CT images) Victor Cheng, M.D. Director, Cardiovascular CT Oklahoma Heart Institute 1 Disclosures Tornadoes scare me 2 Treating CAD Fixing
More informationCMR stress Perfusion: what's new?
CMR stress Perfusion: what's new? John P. Greenwood Professor of Cardiology, Leeds University, UK Consultant Cardiologist Leeds Teaching Hospitals NHS Trust, UK CMR: multi-parametric CMR: multi-parametric
More informationESC CONGRESS 2010 Stockholm, august 28 september 1, 2010
ESC CONGRESS 2010 Stockholm, august 28 september 1, 2010 CORONARY ARTERY DISEASE AND NUCLEAR IMAGING: AN UPDATE PERFUSION SCINTIGRAPHY IN HIGH-RISK ASYMPTOMATIC PATIENTS Pasquale Perrone Filardi Federico
More informationFFR= Qs/Qn. Ohm s law R= P/Q Q=P/R
32 ο Πανελλήνιο Καρδιολογικό Συνζδριο, Θεσσαλονίκη 20/10/2011 Gould KL et al, JACC CARDIOVASC IMAG 2009 Gould KL et al AM J CARDIOL 1974 & JACC CARDIOVASC IMAG 2009 Under maximal hyperemia: Rs=Rn FFR=
More informationDavid A. Orsinelli, MD, FACC, FASE Professor, Internal Medicine The Ohio State University Division of Cardiovascular Medicine Columbus, Ohio
1 STABLE ISCHEMIC HEART DISEASE: A NON-INVASIVE CARDIOLOGIST S PERSECTIVE 2018 Cardiovascular Course for Trainees and Early Career Physicians APRIL 20, 2018 David A. Orsinelli, MD, FACC, FASE Professor,
More informationHybrid cardiac imaging Advantages, limitations, clinical scenarios and perspectives for the future
Hybrid cardiac imaging Advantages, limitations, clinical scenarios and perspectives for the future Prof. Juhani Knuuti, MD, FESC Turku, Finland Disclosure: Juhani Knuuti, M.D. Juhani Knuuti, M.D. has financial
More informationRole of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University
Role of Clopidogrel in Acute Coronary Syndromes Hossam Kandil,, MD Professor of Cardiology Cairo University ACS Treatment Strategies Reperfusion/Revascularization Therapy Thrombolysis PCI (with/ without
More informationBetter CABGs vs Better PCI Devices
CABG vs PCI 2017 Multivessel Coronary Disease Better CABGs vs Better PCI Devices ACC New York, Dec 8, 2017 No Disclosures CABG vs PCI 2017 Stable Multivessel Coronary Disease 1. Are These The two Critical
More informationCASE from South Korea
CASE from South Korea Bon-Kwon Koo, MD, PhD, Seoul, Korea Outpatient clinic of a non-interventional cardiologist F/56 Chief complaint: Angina with recent aggravation, CCS II~III Brief history: # Stroke
More informationFFR and intravascular imaging, which of which?
FFR and intravascular imaging, which of which? Ayman Khairy MD, PhD, FESC Associate professor of Cardiovascular Medicine Vice Director of Assiut University Hospitals Assiut, Egypt Diagnostic assessment
More informationWhat the Cardiologist needs to know from Medical Images
What the Cardiologist needs to know from Medical Images Gerald Maurer Department of Cardiology Medical University of Vienna What kinds of Cardiologists Plumbers Electricians Photographers And then there
More informationFFR in unstable angina and after MI F
FFR in unstable angina and after MI F June-Hong Kim, MD. PhD Cardiovascular center Pusan National University Yangsan Hospital FFR tells you physiologic stenosis severity rather than anatomical stenosis
More informationDiabetic Patients: Current Evidence of Revascularization
Diabetic Patients: Current Evidence of Revascularization Alexandra J. Lansky, MD Yale University School of Medicine University College of London The Problem with Diabetic Patients Endothelial dysfunction
More informationFFR in Left Main Disease
FFR in Left Main Disease William F. Fearon, MD Associate Professor of Medicine Director, Interventional Cardiology Stanford University Medical Center Why FFR instead of IVUS? Physiologic versus anatomic
More informationAntiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease. Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.
Antiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.Κιλκίς Primary CVD Prevention A co-ordinated set of actions,
More informationMalaysian Healthy Ageing Society
Organised by: Co-Sponsored: Malaysian Healthy Ageing Society CAD INVESTIGATIONS PHYSIOLOGICAL / FUNCTIONAL VS ANATOMICAL / STRUCTURAL Disclosure iheal medical centre is a one stop cardiac centre with
More informationClinical Considerations for CTO Revascularization
Clinical Considerations for CTO Revascularization Whom to treat, Who derives benefit and What can we achieve? David E. Kandzari, MD, FACC, FSCAI Chief Medical Officer Cordis Cardiology Johnson & Johnson
More informationLeft Main Intervention: Where are we in 2015?
Left Main Intervention: Where are we in 2015? David A. Cox, MD FSCAI Director, Cardiology Research Associate Director, Cardiac Cath Lab Lehigh Valley Health Network Allentown, PA Fall Fellows Course Laa
More informationCurrent and Future Imaging Trends in Risk Stratification for CAD
Current and Future Imaging Trends in Risk Stratification for CAD Brian P. Griffin, MD FACC Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic Disclosures: None Introduction
More informationCost analysis of non-invasive fractional flow reserve derived from coronary computed tomographic angiography in Japan
Cardiovasc Interv and Ther (2015) 30:38 44 DOI 10.1007/s12928-014-0285-1 ORIGINAL ARTICLE Cost analysis of non-invasive fractional flow reserve derived from coronary computed tomographic angiography in
More informationForm 4: Coronary Evaluation
Form : Coronary Evaluation Print this Form t Started Date of Coronary Evaluation Coronary Evaluation Indication for Coronary Evaluation Check only one. Angio NOT DONE: n invasive test performed Followup
More informationShould we be using fractional flow reserve more routinely to select stable coronary patients for percutaneous coronary intervention?
REVIEW C URRENT OPINION Should we be using fractional flow reserve more routinely to select stable coronary patients for percutaneous coronary intervention? Seung-Jung Park and Jung-Min Ahn Purpose of
More informationVCU Pauley Heart Center: A 2009 US News Top 50 Heart and Heart Surgery Hospital
VCU Pauley Heart Center: A 2009 US News Top 50 Heart and Heart Surgery Hospital Complex PCI: Multivessel Disease George W. Vetrovec, MD. Kimmerling Chair of Cardiology VCU Pauley Heart Center Virginia
More informationDECISION - CTO. optimal Medical Treatment in patients with. Seung-Jung Park, MD, PhD, FACC for the DECISION-CTO Study investigators
DECISION - CTO Drug-Eluting stent Implantation versus optimal Medical Treatment in patients with ChronIc Total OccluSION Seung-Jung Park, MD, PhD, FACC for the DECISION-CTO Study investigators Asan Medical
More informationEXCEL vs. NOBLE: How to Treat Left Main Disease in 2017 AATS International Cardiovascular Symposium December 8-9, 2017
EXCEL vs. NOBLE: How to Treat Left Main Disease in 2017 AATS International Cardiovascular Symposium December 8-9, 2017 Igor F. Palacios, MD Director of Interventional Cardiology Professor of Medicine Massachusetts
More informationFractional Flow Reserve (FFR)
Non-invasive FFR using coronary CT angiography and computational fluid dyn amics predicts the hemodynamic signifi cance of coronary lesions First in man experience with CT-Flow Andrejs Erglis, Sanda Jegere,
More informationJournal of the American College of Cardiology Vol. 35, No. 5, by the American College of Cardiology ISSN /00/$20.
Journal of the American College of Cardiology Vol. 35, No. 5, 2000 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00 Published by Elsevier Science Inc. PII S0735-1097(00)00546-5 CLINICAL
More informationCulprit PCI vs MultiVessel PCI for Acute Myocardial Infarction
Culprit PCI vs MultiVessel PCI for Acute Myocardial Infarction Dipti Itchhaporia, MD, FACC, FESC Trustee, American College of Cardiology Director of Disease Management, Hoag Hospital Robert and Georgia
More informationSevere Left Ventricular Dysfunction: Evolving Revascularization Strategies
Severe Left Ventricular Dysfunction: Evolving Revascularization Strategies Robert O. Bonow, MD, MS, MACC Northwestern University Feinberg School of Medicine Bluhm Cardiovascular Institute Northwestern
More informationReconciling the Results of the Randomized Trials
Management of Stable Angina in Multivessel Disease: Reconciling the Results of the Randomized Trials Eric A. Cohen MD, FRCPC Schulich Heart Centre Sunnybrook Health Sciences Centre Toronto ON ACC Rockies
More informationStress ECG is still Viable in Suleiman M Kharabsheh, MD, FACC Consultant Invasive Cardiologist KFHI KFSHRC-Riyadh
Stress ECG is still Viable in 2016 Suleiman M Kharabsheh, MD, FACC Consultant Invasive Cardiologist KFHI KFSHRC-Riyadh Stress ECG Do we still need stress ECG with all the advances we have in the CV field?
More informationPerioperative Cardiology Consultations for Noncardiac Surgery Ischemic Heart Disease
2012 대한춘계심장학회 Perioperative Cardiology Consultations for Noncardiac Surgery Ischemic Heart Disease 울산의대울산대학병원심장내과이상곤 ECG CLASS IIb 1. Preoperative resting 12-lead ECG may be reasonable in patients with
More informationForm 4: Coronary Evaluation
Patient Details Hidden Show Show/Hide Annotations Form : Coronary Evaluation Print this Form t Started Date of Coronary Evaluation Coronary Evaluation Indication for Coronary Evaluation Check only one.
More informationCardiac CT Angiography
Cardiac CT Angiography Dr James Chafey, Radiologist Why do we need a better test for C.A.D? 1. CAD is the leading cause of death in the US CAD 31% Cancer 23% Stroke 7% 2. The prevalence of atherosclerosis
More informationUse of Nuclear Cardiology in Myocardial Viability Assessment and Introduction to PET and PET/CT for Advanced Users
Use of Nuclear Cardiology in Myocardial Viability Assessment and Introduction to PET and PET/CT for Advanced Users February 1 5, 2011 University of Santo Tomas Hospital Angelo King A-V Auditorium Manila,
More information